Current Research in Medical Sciences
Babol Univesity of Medical Sciences
Wed, Feb 18, 2026
[Archive]
Volume 6, Issue 2 (12-2022)
CRMS 2022, 6(2): 58-63 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadi P, Sedaghat M, Rashvandi Z. Effect of pantoprazole on prevention of gastrointestinal bleeding in acute coronary syndrome patients with high risk of gastrointestinal bleeding. CRMS 2022; 6 (2) :58-63
URL: http://crms.mubabol.ac.ir/article-1-129-en.html
URL: http://crms.mubabol.ac.ir/article-1-129-en.html
Department of Internal Medicine, School of Medicine, shahid Beheshti University of Medical Sciences, Tehran, Iran , Sedaghat@sbmu.ac.ir
Abstract: (1946 Views)
Background and Objective: Determination of best preventive approach for gastrointestinal bleeding in Acute Coronary Syndrome (ACS) patients with high risk of gastrointestinal bleeding is crucial. This study aimed to determine the effect of pantoprazole on prevention of gastrointestinal bleeding in ACS patients with high risk of gastrointestinal bleeding.
Methods: This randomized clinical trial was performed in emergency department of Imam Hussein Hospital in Tehran, Iran between 2018 and 2019 among 1276 consecutive ACS patients with high risk of gastrointestinal bleeding.The participants were randomly received either pantoprazole 40 mg or famotidine 40 mg daily. The melena, hematemesis, hematochezia, and hemoglobin level were compared across the groups after one month.
Findings: The results in this study demonstrated that melena was seen in 1.1% and 3.8% in pantoprazole and famotidine groups, respectively with significant difference (P=0.002). Hematemesis was seen in 0.6% and 1.9% in pantoprazole and famotidine groups, respectively with significant difference (P=0.044). Also, hematochezia was seen in 0.3% and 0.8% in pantoprazole and famotidine groups, respectively without significant difference (P=0.452). The mean hemoglobin was 11.98 and 11.82 in pantoprazole and famotidine groups, respectively with significant difference (P=0.021).
Conclusion: This study showed that pantoprazole (versus famotidine) is effective for prevention of gastrointestinal bleeding in Acute Coronary Syndrome patients with high risk of gastrointestinal bleeding.
Methods: This randomized clinical trial was performed in emergency department of Imam Hussein Hospital in Tehran, Iran between 2018 and 2019 among 1276 consecutive ACS patients with high risk of gastrointestinal bleeding.The participants were randomly received either pantoprazole 40 mg or famotidine 40 mg daily. The melena, hematemesis, hematochezia, and hemoglobin level were compared across the groups after one month.
Findings: The results in this study demonstrated that melena was seen in 1.1% and 3.8% in pantoprazole and famotidine groups, respectively with significant difference (P=0.002). Hematemesis was seen in 0.6% and 1.9% in pantoprazole and famotidine groups, respectively with significant difference (P=0.044). Also, hematochezia was seen in 0.3% and 0.8% in pantoprazole and famotidine groups, respectively without significant difference (P=0.452). The mean hemoglobin was 11.98 and 11.82 in pantoprazole and famotidine groups, respectively with significant difference (P=0.021).
Conclusion: This study showed that pantoprazole (versus famotidine) is effective for prevention of gastrointestinal bleeding in Acute Coronary Syndrome patients with high risk of gastrointestinal bleeding.
Type of Study: Original Article |
Subject:
داخلی
Received: 2022/12/7 | Accepted: 2022/12/25 | Published: 2023/01/28
Received: 2022/12/7 | Accepted: 2022/12/25 | Published: 2023/01/28
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
